EUCTR2008-004745-28-AT进行中（未招募）1 期
Certican (Everolimus®) against Cytomegalovirus Disease in Renal Transplant Patients
Medizinische Universität Wien, KIM III, Abteilung für Nephrologie0 个研究点开始时间: 2008年8月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •CMV-disease after renal transplantation, i.e.(1.) CMV present in the blood, and (2.) one of the following symptoms (for viral syndrome, from the Amercan Society of Transplantation recommendations for use in clinical trials): body temperature =38°C, new or increased significant malaise, leucopenia (<3500/mL), atypical lymphocytosis =5%, thrombocytopaenia (platelets <100.000/mL)
- •informed consent of the patient
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •acute rejection episodes in the first 3 months after renal transplantation
- •active hepatitis in the month prior
- •hematocrit <25%
- •any significant wound healing disorder
- •blood white blood cell (WBC) count <3000/mL
- •platelets <50.000/mL
- •severe dyslipidemia (cholesterol >300mg/dL, triglycerides >350mg/dL))
- •uncontrolled hypertension
- •uncontrolled hyperuricemia
研究者
相似试验
Unknown
2 期
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant PatientsCytomegalovirus DiseaseNCT00828503Marcus Saemann40
招募中
不适用
Efficacy and safety of everolimus (Certican) plus once-daily prolonged-release tacrolimus (Graceptor) combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial.Kidney transplantationJPRN-UMIN000011562Tokyo Women's Medical University, Dep. Urology120
招募中
3 期
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: a multicenter, open-label randomized controlled clinical trialHIV/AIDSCytomegalovirus pneumoniaRespiratoryPaediatricsTuberculosisPACTR201904797961340Servicio Madrileno de Salud Fundacion para la Investigacion Biomedica Hospital Universitario 12 de Octubre624
已完成
4 期
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsChronic Renal FailureNCT00965094Novartis Pharmaceuticals36
已完成
3 期
CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control groupcongenital cytomegalovirus (CMV)100407921001924310012562NL-OMON41461eids Universitair Medisch Centrum50